Skip to main content
NCBI home page
Molecular and Cellular Biology logoLink to Molecular and Cellular Biology
. 1997 May;17(5):2806–2815. doi: 10.1128/mcb.17.5.2806

Proteolysis by calpains: a possible contribution to degradation of p53.

M Pariat 1, S Carillo 1, M Molinari 1, C Salvat 1, L Debüssche 1, L Bracco 1, J Milner 1, M Piechaczyk 1
PMCID: PMC232132  PMID: 9111352

Abstract

p53 is a short-lived transcription factor that is frequently mutated in tumor cells. Work by several laboratories has already shown that the ubiquitin-proteasome pathway can largely account for p53 destruction, at least under specific experimental conditions. We report here that, in vitro, wild-type p53 is a sensitive substrate for milli- and microcalpain, which are abundant and ubiquitous cytoplasmic proteases. Degradation was dependent on p53 protein conformation. Mutants of p53 with altered tertiary structure displayed a wide range of susceptibility to calpains, some of them being largely resistant to degradation and others being more sensitive. This result suggests that the different mutants tested here adopt slightly different conformations to which calpains are sensitive but that cannot be discriminated by using monoclonal antibodies such as PAb1620 and PAb240. Inhibition of calpains by using the physiological inhibitor calpastatin leads to an elevation of p53 steady-state levels in cells expressing wild-type p53. Conversely, activation of calpains by calcium ionophore led to a reduction of p53 in mammalian cells, and the effect was blocked by cell-permeant calpain inhibitors. Cotransfection of p53-null cell lines with p53 and calpastatin expression vectors resulted in an increase in p53-dependent transcription activity. Taken together, these data support the idea that calpains may also contribute to the regulation of wild-type p53 protein levels in vivo.

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakalkin G., Yakovleva T., Selivanova G., Magnusson K. P., Szekely L., Kiseleva E., Klein G., Terenius L., Wiman K. G. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):413–417. doi: 10.1073/pnas.91.1.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bargonetti J., Friedman P. N., Kern S. E., Vogelstein B., Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell. 1991 Jun 14;65(6):1083–1091. doi: 10.1016/0092-8674(91)90560-l. [DOI] [PubMed] [Google Scholar]
  3. Bargonetti J., Manfredi J. J., Chen X., Marshak D. R., Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 1993 Dec;7(12B):2565–2574. doi: 10.1101/gad.7.12b.2565. [DOI] [PubMed] [Google Scholar]
  4. Carillo S., Pariat M., Steff A. M., Roux P., Etienne-Julan M., Lorca T., Piechaczyk M. Differential sensitivity of FOS and JUN family members to calpains. Oncogene. 1994 Jun;9(6):1679–1689. [PubMed] [Google Scholar]
  5. Carillo S., Pariat M., Steff A. m., Jariel-Encontre I., Poulat F., Berta P., Piechaczyk M. PEST motifs are not required for rapid calpain-mediated proteolysis of c-fos protein. Biochem J. 1996 Jan 1;313(Pt 1):245–251. doi: 10.1042/bj3130245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992 Jan 24;255(5043):459–462. doi: 10.1126/science.1346476. [DOI] [PubMed] [Google Scholar]
  7. Chiu R., Boyle W. J., Meek J., Smeal T., Hunter T., Karin M. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell. 1988 Aug 12;54(4):541–552. doi: 10.1016/0092-8674(88)90076-1. [DOI] [PubMed] [Google Scholar]
  8. Chowdary D. R., Dermody J. J., Jha K. K., Ozer H. L. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol. 1994 Mar;14(3):1997–2003. doi: 10.1128/mcb.14.3.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ciechanover A., Shkedy D., Oren M., Bercovich B. Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. J Biol Chem. 1994 Apr 1;269(13):9582–9589. [PubMed] [Google Scholar]
  10. Croall D. E., DeMartino G. N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev. 1991 Jul;71(3):813–847. doi: 10.1152/physrev.1991.71.3.813. [DOI] [PubMed] [Google Scholar]
  11. Delphin C., Cahen P., Lawrence J. J., Baudier J. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur J Biochem. 1994 Jul 15;223(2):683–692. doi: 10.1111/j.1432-1033.1994.tb19041.x. [DOI] [PubMed] [Google Scholar]
  12. Donehower L. A., Bradley A. The tumor suppressor p53. Biochim Biophys Acta. 1993 Aug 23;1155(2):181–205. doi: 10.1016/0304-419x(93)90004-v. [DOI] [PubMed] [Google Scholar]
  13. Dulić V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994 Mar 25;76(6):1013–1023. doi: 10.1016/0092-8674(94)90379-4. [DOI] [PubMed] [Google Scholar]
  14. Farmer G., Bargonetti J., Zhu H., Friedman P., Prywes R., Prives C. Wild-type p53 activates transcription in vitro. Nature. 1992 Jul 2;358(6381):83–86. doi: 10.1038/358083a0. [DOI] [PubMed] [Google Scholar]
  15. Fields S., Jang S. K. Presence of a potent transcription activating sequence in the p53 protein. Science. 1990 Aug 31;249(4972):1046–1049. doi: 10.1126/science.2144363. [DOI] [PubMed] [Google Scholar]
  16. Fujiwara T., Cai D. W., Georges R. N., Mukhopadhyay T., Grimm E. A., Roth J. A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994 Oct 5;86(19):1458–1462. doi: 10.1093/jnci/86.19.1458. [DOI] [PubMed] [Google Scholar]
  17. Funk W. D., Pak D. T., Karas R. H., Wright W. E., Shay J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol. 1992 Jun;12(6):2866–2871. doi: 10.1128/mcb.12.6.2866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ginsberg D., Mechta F., Yaniv M., Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9979–9983. doi: 10.1073/pnas.88.22.9979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Goldberg A. L., Rock K. L. Proteolysis, proteasomes and antigen presentation. Nature. 1992 Jun 4;357(6377):375–379. doi: 10.1038/357375a0. [DOI] [PubMed] [Google Scholar]
  20. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  21. Gronostajski R. M., Goldberg A. L., Pardee A. B. Energy requirement for degradation of tumor-associated protein p53. Mol Cell Biol. 1984 Mar;4(3):442–448. doi: 10.1128/mcb.4.3.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hershko A., Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem. 1992;61:761–807. doi: 10.1146/annurev.bi.61.070192.003553. [DOI] [PubMed] [Google Scholar]
  23. Hirai S., Kawasaki H., Yaniv M., Suzuki K. Degradation of transcription factors, c-Jun and c-Fos, by calpain. FEBS Lett. 1991 Aug 5;287(1-2):57–61. doi: 10.1016/0014-5793(91)80015-u. [DOI] [PubMed] [Google Scholar]
  24. Jennissen H. P. Ubiquitin and the enigma of intracellular protein degradation. Eur J Biochem. 1995 Jul 1;231(1):1–30. [PubMed] [Google Scholar]
  25. Kastan M. B., Zhan Q., el-Deiry W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., Fornace A. J., Jr A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992 Nov 13;71(4):587–597. doi: 10.1016/0092-8674(92)90593-2. [DOI] [PubMed] [Google Scholar]
  26. Kern S. E., Kinzler K. W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991 Jun 21;252(5013):1708–1711. doi: 10.1126/science.2047879. [DOI] [PubMed] [Google Scholar]
  27. Kern S. E., Pietenpol J. A., Thiagalingam S., Seymour A., Kinzler K. W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992 May 8;256(5058):827–830. doi: 10.1126/science.1589764. [DOI] [PubMed] [Google Scholar]
  28. Kinzler K. W., Vogelstein B. Life (and death) in a malignant tumour. Nature. 1996 Jan 4;379(6560):19–20. doi: 10.1038/379019a0. [DOI] [PubMed] [Google Scholar]
  29. Ko L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996 May 1;10(9):1054–1072. doi: 10.1101/gad.10.9.1054. [DOI] [PubMed] [Google Scholar]
  30. Kubbutat M. H., Vousden K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol. 1997 Jan;17(1):460–468. doi: 10.1128/mcb.17.1.460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  32. Lane R. D., Allan D. M., Mellgren R. L. A comparison of the intracellular distribution of mu-calpain, m-calpain, and calpastatin in proliferating human A431 cells. Exp Cell Res. 1992 Nov;203(1):5–16. doi: 10.1016/0014-4827(92)90033-5. [DOI] [PubMed] [Google Scholar]
  33. Legros Y., Lacabanne V., d'Agay M. F., Larsen C. J., Pla M., Soussi T. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer. 1993 Feb;80(2):102–110. [PubMed] [Google Scholar]
  34. Léveillard T., Andera L., Bissonnette N., Schaeffer L., Bracco L., Egly J. M., Wasylyk B. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 1996 Apr 1;15(7):1615–1624. [PMC free article] [PubMed] [Google Scholar]
  35. Maki C. G., Huibregtse J. M., Howley P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 1;56(11):2649–2654. [PubMed] [Google Scholar]
  36. Maki M., Bagci H., Hamaguchi K., Ueda M., Murachi T., Hatanaka M. Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. J Biol Chem. 1989 Nov 15;264(32):18866–18869. [PubMed] [Google Scholar]
  37. Masuda H., Miller C., Koeffler H. P., Battifora H., Cline M. J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7716–7719. doi: 10.1073/pnas.84.21.7716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Medcalf E. A., Takahashi T., Chiba I., Minna J., Milner J. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. Oncogene. 1992 Jan;7(1):71–76. [PubMed] [Google Scholar]
  39. Mellgren R. L., Lu Q. Selective nuclear transport of mu-calpain. Biochem Biophys Res Commun. 1994 Oct 28;204(2):544–550. doi: 10.1006/bbrc.1994.2493. [DOI] [PubMed] [Google Scholar]
  40. Mellgren R. L. Proteolysis of nuclear proteins by mu-calpain and m-calpain. J Biol Chem. 1991 Jul 25;266(21):13920–13924. [PubMed] [Google Scholar]
  41. Mellgren R. L., Song K., Mericle M. T. m-Calpain requires DNA for activity on nuclear proteins at low calcium concentrations. J Biol Chem. 1993 Jan 5;268(1):653–657. [PubMed] [Google Scholar]
  42. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 1990 Aug 24;62(4):671–680. doi: 10.1016/0092-8674(90)90113-s. [DOI] [PubMed] [Google Scholar]
  43. Milner J., Chan Y. S., Medcalf E. A., Wang Y., Eckhart W. Partially transformed T3T3 cells express high levels of mutant p53 in the 'wild-type' immunoreactive form with defective oligomerization. Oncogene. 1993 Jul;8(7):2001–2008. [PubMed] [Google Scholar]
  44. Milner J. Flexibility: the key to p53 function? Trends Biochem Sci. 1995 Feb;20(2):49–51. doi: 10.1016/s0968-0004(00)88954-9. [DOI] [PubMed] [Google Scholar]
  45. Milner J. Forms and functions of p53. Semin Cancer Biol. 1994 Jun;5(3):211–219. [PubMed] [Google Scholar]
  46. Milner J., Medcalf E. A. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. J Mol Biol. 1990 Dec 5;216(3):481–484. doi: 10.1016/0022-2836(90)90371-R. [DOI] [PubMed] [Google Scholar]
  47. Molinari M., Milner J. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. Oncogene. 1995 May 4;10(9):1849–1854. [PubMed] [Google Scholar]
  48. Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 1995 Sep 15;14(18):4442–4449. doi: 10.1002/j.1460-2075.1995.tb00123.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Okamoto K., Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 1994 Oct 17;13(20):4816–4822. doi: 10.1002/j.1460-2075.1994.tb06807.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol. 1994 Jun;5(3):221–227. [PubMed] [Google Scholar]
  51. Oren M. p53: the ultimate tumor suppressor gene? FASEB J. 1992 Oct;6(13):3169–3176. doi: 10.1096/fasebj.6.13.1397838. [DOI] [PubMed] [Google Scholar]
  52. Pavletich N. P., Chambers K. A., Pabo C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993 Dec;7(12B):2556–2564. doi: 10.1101/gad.7.12b.2556. [DOI] [PubMed] [Google Scholar]
  53. Raycroft L., Wu H. Y., Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990 Aug 31;249(4972):1049–1051. doi: 10.1126/science.2144364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rolley N., Butcher S., Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene. 1995 Aug 17;11(4):763–770. [PubMed] [Google Scholar]
  55. Saido T. C., Sorimachi H., Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 1994 Aug;8(11):814–822. [PubMed] [Google Scholar]
  56. Scheffner M., Huibregtse J. M., Howley P. M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8797–8801. doi: 10.1073/pnas.91.19.8797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Scheffner M., Nuber U., Huibregtse J. M. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature. 1995 Jan 5;373(6509):81–83. doi: 10.1038/373081a0. [DOI] [PubMed] [Google Scholar]
  58. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129–1136. doi: 10.1016/0092-8674(90)90409-8. [DOI] [PubMed] [Google Scholar]
  59. Schweighoffer F., Barlat I., Chevallier-Multon M. C., Tocque B. Implication of GAP in Ras-dependent transactivation of a polyoma enhancer sequence. Science. 1992 May 8;256(5058):825–827. doi: 10.1126/science.1317056. [DOI] [PubMed] [Google Scholar]
  60. Shkedy D., Gonen H., Bercovich B., Ciechanover A. Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system. FEBS Lett. 1994 Jul 11;348(2):126–130. doi: 10.1016/0014-5793(94)00582-6. [DOI] [PubMed] [Google Scholar]
  61. Sturges M. R., Peck L. J. Calcium-dependent inactivation of RNA polymerase III transcription. J Biol Chem. 1994 Feb 25;269(8):5712–5719. [PubMed] [Google Scholar]
  62. Stürzbecher H. W., Donzelmann B., Henning W., Knippschild U., Buchhop S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 1996 Apr 15;15(8):1992–2002. [PMC free article] [PubMed] [Google Scholar]
  63. Subler M. A., Martin D. W., Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol. 1992 Aug;66(8):4757–4762. doi: 10.1128/jvi.66.8.4757-4762.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Ueba T., Nosaka T., Takahashi J. A., Shibata F., Florkiewicz R. Z., Vogelstein B., Oda Y., Kikuchi H., Hatanaka M. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9009–9013. doi: 10.1073/pnas.91.19.9009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Unger T., Nau M. M., Segal S., Minna J. D. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 1992 Apr;11(4):1383–1390. doi: 10.1002/j.1460-2075.1992.tb05183.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Watt F., Molloy P. L. Specific cleavage of transcription factors by the thiol protease, m-calpain. Nucleic Acids Res. 1993 Nov 11;21(22):5092–5100. doi: 10.1093/nar/21.22.5092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Yamato K., Yamamoto M., Hirano Y., Tsuchida N. A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes. Oncogene. 1995 Jul 6;11(1):1–6. [PubMed] [Google Scholar]
  68. Zambetti G. P., Levine A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993 Jul;7(10):855–865. doi: 10.1096/fasebj.7.10.8344485. [DOI] [PubMed] [Google Scholar]
  69. Zerrahn J., Deppert W., Weidemann D., Patschinsky T., Richards F., Milner J. Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene. 1992 Jul;7(7):1371–1381. [PubMed] [Google Scholar]
  70. Zhang W., Lu Q., Xie Z. J., Mellgren R. L. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene. 1997 Jan 23;14(3):255–263. doi: 10.1038/sj.onc.1200841. [DOI] [PubMed] [Google Scholar]
  71. el-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992 Apr;1(1):45–49. doi: 10.1038/ng0492-45. [DOI] [PubMed] [Google Scholar]
  72. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]

Articles from Molecular and Cellular Biology are provided here courtesy of Taylor & Francis

RESOURCES